Not actual patients.
Designed to fit your lifestyle
Why HYMPAVZI?
Learn what sets it apart.
Proven bleed protection*
HYMPAVZI was shown to help protect hemophilia A & B patients from bleeds.*
Fixed-dose,†prefilled pen
A set dose comes in each pen, so you don't need to mix or measure.
Innovative
HYMPAVZI works to help achieve hemostasis (how your body stops or prevents bleeding) through rebalancing the clotting process.
Subcutaneous delivery
HYMPAVZI is injected under the skin, not into a vein.
No mandatory treatment-related lab monitoring
Talk to your doctor about lab monitoring that may be necessary for your condition.
- In the BASIS study, patients ages 12+ without inhibitors achieved a 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment (3.2 ABR vs 39.9 ABR) and a 35% reduction in treated bleeds on HYMPAVZI compared with routine factor-based prophylaxis treatment (5.1 ABR vs 7.9 ABR). Patients ages 12+ with inhibitors achieved a 93% reduction in treated bleeds on HYMPAVZI compared with on-demand bypass agent treatment (1.4 ABR vs 19.8 ABR).
- HYMPAVZI is available in 75 mg and 150 mg pens. For children ages 6 to less than 12, the first dose (loading dose) is 150 mg on day 1. Then a weekly (maintenance) dose of 75 mg as prescribed by your healthcare provider. For adults and adolescents 12+, the first dose (loading dose) is 300 mg on day 1. Then a weekly (maintenance) dose of 150 mg as prescribed by your healthcare provider. If more than 1 injection is required to deliver a complete dose, administer each injection at a different site.
HYMPAVZI has been studied in 2 clinical trials. See study results.
Learn how HYMPAVZI works